TNXP - トニックス・ファ―マシュ―ティカルズ （Tonix Pharmaceuticals Holding Corp.）

The trading price of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) closed higher on Monday, October 03, closing at $0.55, 2.94% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $0.5435 and $0.62. In examining the 52-week price action we see that the stock hit a … Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Is Down -95.20% So Far This Year: What Will Happen Next? Read More »

The U.S. Food and Drug Administration ((FDA)) cleared Tonix Pharmaceuticals'' (TNXP) application seeking to start a phase 2 of TNX-601 ER to treat major depressive disorder…

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) price closed lower on Monday, September 26, dropping -3.62% below its previous close. A look at the daily price movement shows that the last close reads $0.55, with intraday deals fluctuated between $0.5215 and $0.57. The company’s 5Y monthly beta was ticking 1.53. Taking into account the 52-week price action … Analyze Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Before Investing. Read More »

In Friday’s session, Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) marked $0.55 per share, down from $0.57 in the previous session. While Tonix Pharmaceuticals Holding Corp. has underperformed by -3.34%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, TNXP fell by -97.25%, with highs and lows ranging from […]

New Jersey, NJ -- ( SBWIRE ) -- 09/26/2022 -- HTF MI introduces new research on Global Monkeypox Vaccine covering the micro level of analysis by competitors and key business segments. The Global Monkeypox Vaccine explores a comprehensive study on various segments like opportunities, size, development, innovation, sales, and overall growth of major players. The research is carried out on primary and secondary statistics sources and it consists of both qualitative and quantitative detailing. Some of the major key players profiled in the study are Emergent BioSolutions Inc. (United States), Wyeth Laboratories, Inc. (United States), Bavarian Nordic (Denmark), Sanofi Pasteur Biologics LLC. (United States), Chimerix (United States), Nanotherapeutics (United States), SIGA Technologies (United States), TapImmune (United States), Tonix Pharmaceuticals Holding (United States) and CEL-SCI (United States). Acquire Sample Report + All Related Table and Graphs@: https://www.htfmarketreport.com/sample-report/4151437-global-monkeypox-vaccine-market-1 Monkeypox is a viral zoonotic complaint that occurs primarily in tropical rainforest areas of central and West Africa and is sometimes exported to other regions.

NEW YORK , March 7, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VEON, NIO, RIG, CLOV, and TNXP. … Full story available on Benzinga.com

Full story available on Benzinga.com

An Investigator Initiated Phase 2 Clinical Trial of TNX-1900 In Patients with Binge Eating Disorder Planned for Second Half 2022 Binge Eating Disorder is Estimated to Affect 2.8 Million American Adults1-3 Expands Uses of Tonix’s Proprietary Potentiated Oxytocin for Intranasal Administration to a Potential New Indication CHATHAM, N.J., March 07, 2022 (GLOBE NEWSWIRE) — Tonix … The post Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder appeared first on ForexTV .

Buyers are unwinding their trades in a big way, following through on the profit-taking they initiated yesterday.

NEW YORK , March 4, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VEON, EJH, TNXP, AAL, and OCGN. … Full story available on Benzinga.com

There is a good chance Tonix Pharmaceuticals (NASDAQ: TNXP ) breaks the support at $1 and moves lower. There's support at this level because it's important psychologically. Many investors like to place their orders at nice round levels and that’s the case here. When TNXP fell to $1 in early March, a rally followed. But that may … Full story available on Benzinga.com

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) and privately-held OyaGen Inc have entered into an exclusive worldwide licensing agreement for TNX-3500 (sangivamycin, formerly OYA1) for the treatment of COVID-19 and potentially other viral disorders. Under the terms of the agreement, Tonix will conduct further studies to test the safety and efficacy of TNX-3500 in treating COVID-19. The financial details of the deal were … Full story available on Benzinga.com

Earnings, Analyst opinion and estimate and latest Covid-19 (Coronavirus) impact on these hot stocks to invest

The following article is sponsored by the clinical communications unit of Redington, Inc. which is paid by Tonix Pharmaceuticals Holding Corp. to provide investor communications services. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Clinical-stage biopharmaceutical company Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ) announced late last year positive results for the first of two pivotal Phase 3 studies of its lead fibromyalgia drug candidate, TNX-102 SL. The company reported that the results from its Phase 3 RELIEF study revealed TNX-102 SL provided statistically significant daily pain reduction over placebo while also being well-tolerated by participants in the study. “We are delighted with the results of our first positive Phase 3 study of TNX-102 SL for the management of fibromyalgia,” said Tonix Pharmaceuticals CEO, Dr. Seth Lederman. “RELIEF is the first of two studies that are required for approval by the U.S.

NEW YORK, NY / ACCESSWIRE / February 13, 2021 / New To The Street will broadcast Show 151 Sunday 930AM EST on NEWSMAX T.V., and on FOX Business Monday evening 1030PM PST. The show will feature Doctor Seth Lederman President and co-founder Tonix Pharma, a research driven biotechnology company. Tonix is working on a 1… Read More »NewtoTheStreet’s Newsmax Sunday 930AM EST Lineup Features Tonix Pharmaceuticals Holding Corp., Nextech AR, Winston Gold and NativeCoin